GRANT NUMBER: DAMD17-94-J-4498

TITLE: The Role of Heparin-Binding EGF-Like Growth Factor in Breast Cancer

PRINCIPAL INVESTIGATOR: Dr. David Salomon

CONTRACTING ORGANIZATION: National Institutes of Health
Bethesda, Maryland 20892

REPORT DATE: October 1995

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
The Role of Heparin-Binding EGF-Like Growth Factor in Breast Cancer

Dr. David Salomon
National Institutes of Health
Bethesda, Maryland 20892

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Approved for public release; distribution unlimited

See statement on page 4.
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

<table>
<thead>
<tr>
<th>Accession For</th>
</tr>
</thead>
<tbody>
<tr>
<td>NTIS GRAI</td>
</tr>
<tr>
<td>DTIC TAB</td>
</tr>
<tr>
<td>Unannounced</td>
</tr>
<tr>
<td>Justification</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Distribution/ Availability Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avail and/or</td>
</tr>
</tbody>
</table>

PI - Signature  9/1/95
Summary of Grant Number DAMD17-94-J-4498

To date no monies have been utilized from the postdoctoral research support grant that was awarded to Dr. Isabelle M. Lacaci. Dr. Lacaci just started to work in my laboratory as of September 5, 1995. She just recently received her Ph. D. degree from Georgetown University in Washington, DC. Dr. Lacaci will be assessing the EGF-related peptide, heparin binding EGF-like growth factor (HB-EGF). Dr. Lacaci will be assessing whether this cytokine is expressed in human breast cancer cells and whether its expression is regulated by hormones that are central in the development of breast cancer. In addition, Dr. Lacai will be determining whether HB-EGF is functioning as an autocrine growth factor for breast cancer cells and if so does interference in its expression perturb the growth of breast cancer cells.